Literature DB >> 23135578

Multimodality salvage of recurrent disease after local excision for rectal cancer.

Y Nancy You1, Robert E Roses, George J Chang, Miguel A Rodriguez-Bigas, Barry W Feig, Rebecca Slack, Sa Nguyen, John M Skibber.   

Abstract

BACKGROUND: Local excision, alone or in combination with chemoradiation, is increasingly considered for rectal cancer. Higher risks of disease recurrence have been demonstrated after local excision.
OBJECTIVE: The aim of this study was to examine the outcomes of current-era multimodality salvage for recurrent rectal cancer after local excision.
DESIGN: This was a single-institutional retrospective study. SETTINGS: This study was conducted at a tertiary-referral cancer center between 1993 and 2011. PATIENTS: Forty-six patients with recurrent rectal cancer after initial local excision were included. INTERVENTION: Multimodality salvage treatment was performed as appropriate. MAIN OUTCOME MEASURES: The primary outcomes measured were the pattern of disease recurrence, salvage treatments, and resultant overall and re-recurrence-free survival.
RESULTS: After the initial local excision, recurrent disease was diagnosed after a median interval of 1.9 years: local/regionally in 67%, distantly in 18%, and both in 15%. Four patients (9%) had recurrence that was unsalvageable, 2 (4%) declined treatment, and 40 (87%) underwent surgical salvage. Preoperative chemoradiation was given in 30 (75%) patients. The R0 resection rate was 80%, requiring multivisceral resection (33%), total pelvic exenteration (5%), and metastasectomy (25%). The rate of sphincter preservation was 33%, and perioperative morbidity was 50%. The first site of failure after salvage was distant in 38% and was local only in 10%. The 5-year overall and 3-year re-recurrence-free survival were 63% and 43%. Pathologic stage at initial local excision, receipt of neoadjuvant chemoradiation before local excision, recurrence pattern after local excision, pathologic stage at salvage, and R0 resection at salvage influenced re-recurrence-free survival. LIMITATIONS: This study was limited by the referral and selection biases inherent in a small study cohort.
CONCLUSIONS: Failure after local excision for rectal cancer may not be salvageable. When feasible, multimodality treatment, including multivisceral resection, pelvic irradiation, and chemotherapy, was associated with potentially lasting treatment-related morbidities and only modest success in long-term disease control. These findings should be compared with the expected stage-specific outcomes of standard proctectomy for early-stage rectal cancer, when local excision is being considered.

Entities:  

Mesh:

Year:  2012        PMID: 23135578     DOI: 10.1097/DCR.0b013e318270837f

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  12 in total

1.  The Role of Transanal Surgery in the Management of T1 Rectal Cancers.

Authors:  Imran Hassan; Paul E Wise; David A Margolin; James W Fleshman
Journal:  J Gastrointest Surg       Date:  2015-06-06       Impact factor: 3.452

2.  Anti-miRNA-221 sensitizes human colorectal carcinoma cells to radiation by upregulating PTEN.

Authors:  Qi Xue; Kai Sun; Hai-Jun Deng; Shang-Tong Lei; Jing-Qing Dong; Guo-Xin Li
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

3.  Analysis of local recurrences after transanal endoscopic microsurgery for low risk rectal carcinoma.

Authors:  Theodor Junginger; Ursula Goenner; Mirjam Hitzler; Tong T Trinh; Achim Heintz; Wilfried Roth; Maria Blettner; Daniel Wollschlaeger
Journal:  Int J Colorectal Dis       Date:  2016-11-25       Impact factor: 2.571

4.  Are we doing too much?: local excision before radical surgery in early rectal cancer.

Authors:  Sun Min Park; Bong-Hyeon Kye; Min Ki Kim; Heba E Jalloun; Hyeon-Min Cho; In Kyu Lee
Journal:  Int J Colorectal Dis       Date:  2018-02-14       Impact factor: 2.571

5.  Surveillance Intensity Comparison by Risk for T1NX Locally Excised Rectal Adenocarcinoma: a Cost-Effective Analysis.

Authors:  Mason McCain; Yohanis O'Neill; Hernan Hernandez; Ryan Foley; Brian M Sadowski; Zachary Torgersen; Jennifer Beaty; Ruben Rojas Payacan; Charles A Ternent
Journal:  J Gastrointest Surg       Date:  2019-11-13       Impact factor: 3.452

6.  Neoadjuvant chemoradiation followed by transanal local excision for T2 rectal cancer confers equivalent survival benefit as traditional transabdominal resection.

Authors:  Oliver K Jawitz; Mohamed A Adam; Megan C Turner; Brian F Gilmore; John Migaly
Journal:  Surgery       Date:  2019-03-21       Impact factor: 3.982

Review 7.  Locally Recurrent Rectal Cancer According to a Standardized MRI Classification System: A Systematic Review of the Literature.

Authors:  Zena Rokan; Constantinos Simillis; Christos Kontovounisios; Brendan Moran; Paris Tekkis; Gina Brown
Journal:  J Clin Med       Date:  2022-06-18       Impact factor: 4.964

8.  Prognosis of Patients Over 60 Years Old With Early Rectal Cancer Undergoing Transanal Endoscopic Microsurgery - A Single-Center Experience.

Authors:  Mingqing Zhang; Yongdan Zhang; Haoren Jing; Lizhong Zhao; Mingyue Xu; Hui Xu; Siwei Zhu; Xipeng Zhang
Journal:  Front Oncol       Date:  2022-06-14       Impact factor: 5.738

9.  Systematic review of classification systems for locally recurrent rectal cancer.

Authors:  Z Rokan; C Simillis; C Kontovounisios; B J Moran; P Tekkis; G Brown
Journal:  BJS Open       Date:  2021-05-07

10.  Practice patterns and long-term survival for early-stage rectal cancer.

Authors:  Karyn B Stitzenberg; Hanna K Sanoff; Dolly C Penn; Michael O Meyers; Joel E Tepper
Journal:  J Clin Oncol       Date:  2013-10-28       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.